{"url_path":"/sec/tnya/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-286957-index.html","accession_number":"0001193125-26-286957","cik":"0001858848","ticker":"TNYA","issuer_name":"Tenaya Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-286957-index.html","primary_entity_key":"0001858848","primary_entity_name":"Tenaya Therapeutics, Inc."},"word_count":114,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure\n\n \n\nOn June 29, 2026, the Company issued a press release announcing Mr. Hyllengren’s appointment as Chief Financial Officer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report. The information in this Item 7.01, including Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}